Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATG-012 + AZD0364 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATG-012 | ATG 012|ATG012 | KRAS G12C inhibitor 34 | ATG-012 inhibits KRAS G12C, potentially resulting in inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2679). | |
AZD0364 | ATG-017|ATG017|ATG 017|AZD-0364|AZD 0364|Tizaterkib | ERK Inhibitor (pan) 21 ERK1 Inhibitor 2 ERK2 Inhibitor 2 | AZD0364 (ATG-017) is a selective ATP-competitive inhibitor of ERK1 and ERK2, which may promote apoptosis and tumor regression (PMID: 31710489, PMID: 33273059). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|